Protocol #0207-544: a phase study to evaluate the safety and pharmacokinetics of Pro-1, a liposome-encapsulated thymidine kinase gene formulation, in patients with stage IV metastatic melanoma.
Thompson
John
J
Seattle Cancer Care Alliance and the University of Washington, USA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D002985:Clinical Protocols; D018014:Gene Transfer Techniques; D006801:Humans; D008081:Liposomes / Q000493:pharmacokinetics*; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics* / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D008081:Liposomes; D013937:Thymidine Kinase